Market Update (NYSE:BAX): PharmaEngine and Merrimack Amend MM-398 License Agreement

[Business Wire] – TAIPEI, Taiwan–(BUSINESSWIRE)– PharmaEngine, Inc. (TWO:4162.TWO – News), announced today that the company has signed an Amendment to its License Agreement of MM-398 (aka PEP02, nanoliposomal irinotecan injection, nal-IRI) with Merrimack . . . → Read More: Market Update (NYSE:BAX): PharmaEngine and Merrimack Amend MM-398 License Agreement Similar Articles: Company Update (NYSE:BAX): Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 Market Update: Baxter International Inc (NYSE:BAX) – Baxter Announces Hemodialysis Dialyzer Expansion in Opelika, Alabama Stock Update: Baxter International Inc (NYSE:BAX) – Baxter to Present at Morgan Stanley Global Healthcare Conference
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.